Galapagos NV
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
25 sep 2015 - 17:08
Statutory name
Galapagos NV
Title
Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
Comments
Galapagos regains all unencumbered rights to filgotinib
Filgotinib is the most selective JAK1 inhibitor
Best-in-class efficacy and safety in RA in 24-week Phase 2B studies in 877 patients
Phase 3 start in RA expected in early 2016
Related downloads
Date last update: 22 July 2025